Abstract: A memory module may be provided. The memory module may include a normal memory device, a spare memory device, and a row hammering determination circuit. The row hammering determination circuit may be configured to control the spare memory device to perform a data input and output operation, instead of a data input and output operation with the normal memory device in which row hammering has occurred.

Abstract: A semiconductor memory apparatus may include a first memory apparatus and a second memory apparatus, and may perform various operation modes. The first and second memory apparatuses may independently perform a write operation and a read operation in a first operation mode. The first memory apparatus may perform a write operation and a read operation and the second memory apparatus may perform a write operation in a second operation mode. The second memory apparatus may perform a write operation and a read operation in a third operation mode.

Abstract: The present invention provides a pharmaceutical formulation comprising clomipramine or its pharmaceutically acceptable salt (preferably, clomipramine hydrochloride) as the first active ingredient, and sildenafil or its pharmaceutically acceptable salt (preferably, sildenafil citrate) as the second active ingredient, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation. In particular, the present invention provides a pharmaceutical formulation comprising the above two active ingredients and manufactured by using a wet granulation method, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation.

Abstract: The present invention provides a pharmaceutical formulation comprising clomipramine or its pharmaceutically acceptable salt (preferably, clomipramine hydrochloride) as the first active ingredient, and sildenafil or its pharmaceutically acceptable salt (preferably, sildenafil citrate) as the second active ingredient, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation. In particular, the present invention provides a pharmaceutical formulation comprising the above two active ingredients and manufactured by using a wet granulation method, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation.

Abstract: A memory module may be provided. The memory module may include a normal memory device, a spare memory device, and a row hammering determination circuit. The row hammering determination circuit may be configured to control the spare memory device to perform a data input and output operation, instead of a data input and output operation with the normal memory device in which row hammering has occurred.

Abstract: The present invention relates to bacterial ghosts, and more particularly, to a method of preparing bacterial ghosts from gram-positive bacteria by hydrochloric acid treatment. Specifically, according to the present invention, when gram-positive bacteria were cultured after being treated with a minimum inhibitory concentration (MIC) of hydrochloric acid capable of inhibiting colony formation of gram-positive bacteria, bacterial ghosts were effectively formed. Since the formed bacterial ghosts have no intracellular proteins or DNA while preserving cell wall integrity, the risk of side effects such as secondary infection caused by bacterial growth when the bacterial ghosts are administered to humans is low. Therefore, the bacterial ghosts prepared from gram-positive bacteria according to the method of the present invention may be effectively used as a vaccine or a foreign antigen carrier for preventing or treating gram-positive bacterial infection.

Abstract: There is provided a method of preparing a fluorescent silk fibroin solution, which includes a) obtaining scoured fluorescent silk fibroin by adding transgenic fluorescent silkworm cocoons to an aqueous solution including a scouring agent, heating the transgenic fluorescent silkworm cocoons at 40 to 60° C. for 8 to 24 hours and washing the transgenic fluorescent silkworm cocoons with distilled water, b) dissolving the scoured fluorescent silk fibroin at 40 to 60° C. for 1 to 5 hours in a solvent in which 15 mg to 1.5 g of dithiothreitol (DTT) is mixed per 100 mL of 9 to 9.6 M LiBr, and c) dialyzing the dissolved fluorescent silk fibroin in single distilled water for 48 to 96 hours. The scouring agent includes an alcalase and sodium hydrogen carbonate (NaHCO3). The conventional methods of preparing a silk fibroin solution from fluorescent silkworm cocoons have drawbacks in that silk fibroin is not dissolved at a low temperature and fluorescence is lost.

Abstract: A fabrication method of a solar cell, the method includes doping a silicon substrate having a first conductive type impurity with a second conductive type impurity, the second conductive type impurity being opposite to the first conductive type impurity, and thereby forming an emitter layer at a front surface part of the silicon substrate, forming an antireflection film on the emitter layer, forming a front electrode on the antireflection film, forming a rear electrode on a rear surface of the silicon substrate, and forming a back surface field layer at a rear surface part of the silicon substrate, the back surface field layer having a concentration of the first conductive type impurity that is higher than that of the silicon substrate, the back surface field layer having a different concentration of the second conductive type impurity from that of the emitter layer.

Abstract: The present invention provides a pharmaceutical formulation comprising clomipramine or its pharmaceutically acceptable salt (preferably, clomipramine hydrochloride) as the first active ingredient, and sildenafil or its pharmaceutically acceptable salt (preferably, sildenafil citrate) as the second active ingredient, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation. In particular, the present invention provides a pharmaceutical formulation comprising the above two active ingredients and manufactured by using a wet granulation method, wherein stability of clomipramine is improved, and a method for manufacturing this pharmaceutical formulation.

Abstract: A method performed at a terminal of a medical team user for changing a medicine-taking schedule includes generating a first medicine-taking schedule, transmitting the first medicine-taking schedule to a terminal of a patient, and receiving a medicine-taking schedule change request from the terminal of the patient. A further operation includes changing the first medicine-taking schedule to a second medicine-taking schedule when a time parameter of the first medicine-taking schedule is within a threshold value of a time parameter of the second medicine-taking schedule.

Abstract: Provided is an apparatus, system, and method related to displaying medicine-taking information, including displaying a first page received from a schedule management server on a display of a patient terminal, the first page including a medicine schedule associated with a particular medicine; displaying a second page separately from the first page on the display, the second page configured for inputting information related to pickup of the particular medicine associated with the medicine schedule; displaying a third page separately from the first page and the second page on the display, the third page including a detailed information button for displaying additional information related to the particular medicine; and transmitting input information for at least the first, second, or third page to the schedule management server.

Abstract: Provided is a medical care provider terminal, a patient terminal and a method for making a video call therebetween. The method may include receiving, at a medical care provider terminal, a video call request from a patient terminal, connecting, at the medical care provider, a video call to the patient terminal, and displaying patient-related information in a first region of a display of the medical care provider terminal and displaying a video call screen in a second region of the display. The video call screen may include a sharing region for sharing with the patient terminal at least one of a first video captured by a camera module connected to the patient terminal, a second video captured by a camera module connected to the medical care provider terminal, the patient-related information, or data input at the medical care provider terminal.

Abstract: Provided is a method of controlling an operation of an image forming apparatus by using a wearable device, the method including operations of converting a task performance request related to a task, which is transmitted from the wearable device, into an execution instruction of a first application that controls the operation of the image forming apparatus; requesting, as the first application is executed based on the execution instruction, the image forming apparatus to perform the task; and receiving, as the task is performed by the image forming apparatus, information indicating a task performance result related to the task from the image forming apparatus.

Abstract: A collagen membrane having fusion protein bound thereto is described, in which the fusion protein includes collagen binding peptide and antibacterial peptide. The collagen membrane is usefully employed in vivo to promote cell migration, proliferation, and differentiation associated with bone tissue regeneration, for bone induction and regeneration. The fusion protein may also be applied to other collagenic graft materials, for use as a biomaterial for regenerating other tissues such as the skin.

Abstract: A fabrication method of a solar cell, the method includes doping a silicon substrate having a first conductive type impurity with a second conductive type impurity, the second conductive type impurity being opposite to the first conductive type impurity, and thereby forming an emitter layer at a front surface part of the silicon substrate, forming an antireflection film on the emitter layer, forming a front electrode on the antireflection film, forming a rear electrode on a rear surface of the silicon substrate, and forming a back surface field layer at a rear surface part of the silicon substrate, the back surface field layer having a concentration of the first conductive type impurity that is higher than that of the silicon substrate, the back surface field layer having a different concentration of the second conductive type impurity from that of the emitter layer.

Abstract: A host device and a driver management method of the host device are provided. The driver management method of the host device includes searching for at least one image scanning device connected to the host device, displaying a list of the at least one image scanning device found as a result of searching, selecting one of the at least one image scanning device from the displayed list, generating a user-specified driver for the selected image scanning device, and adding the generated user-specified driver. Therefore, it is possible to simplify the use of a universal image scanning device driver.

Abstract: A method of controlling a mobile terminal, and which includes controlling, via a Windows processor, a plurality of peripheral devices of the mobile terminal; switching, via the Windows processor, the mobile terminal into a sleep state; granting, via an arbiter control processor, a control authority for controlling predetermined peripheral devices among the plurality of peripheral device to a 3G modem when the mobile terminal is switched into the sleep state; receiving, via a communication unit on the mobile terminal, an incoming call; and managing, via the 3G modem, circuit data and the predetermined peripheral devices for the incoming call.

Abstract: The present invention relates to a pharmaceutical composition for treating, preventing or improving premature ejaculation, which is taken on demand prior to sexual activity, the composition comprising clomipramine hydrochloride in an amount of 14 to 16 mg, preferably about 15 mg, as an active ingredient. More preferably, the composition of the present invention further comprises pregelatinized starch and sodium starch glycolate. The pharmaceutical composition of the present invention can provide rapid onset of efficacy, reduce a dissolution (absorption) deviation according to the patient's gastrointestinal pH conditions and minimize side effects.

Abstract: The present invention relates to a membrane having bound thereto an antibacterial peptide that binds to collagen, and more particularly to a collagen membrane comprising a fusion peptide of a collagen-binding peptide and an antibacterial peptide, fixed to the collagen surface. The present invention provides a collagen membrane having surface activity by a fusion peptide bound to the surface thereof. When the collagen membrane is transplanted in vivo, the retention time of the fusion peptide in a local region can increase, and the fusion peptide can promote the cell migration, proliferation and differentiation associated with bone tissue regeneration, thereby maximizing the ability to regenerate bone tissue. Thus, the collagen membrane contributes to the development of therapeutic technology for bone induction and regeneration. Also, the fusion peptide may be applied to other types of graft materials made of collagen.

Abstract: A host apparatus and a method to share favorite image reading apparatuses thereof are provided. The method to share favorite image reading apparatuses of a host apparatus includes registering at least one of searched image reading apparatuses to a list of favorite image reading apparatuses; selecting at least one of the registered favorite image reading apparatuses to be shared; activating a sharing function to share the selected favorite image reading apparatus; transmitting the list of favorite image reading apparatuses to or receiving a list of favorite image reading apparatuses from another host apparatus of which the sharing function is activated. Therefore, a universal driver may share a list of favorite image reading apparatuses.